Schizophrenia is a neuropsychiatric disorder that chronically affects 21 million people worldwide. Secondgeneration
antipsychotics (SGAs) are the cornerstone in the management of schizophrenia. However,
despite their efficacy in counteracting both positive and negative symptomatology of schizophrenia, recent clinical
observations have described an increase in the prevalence of metabolic disturbances in patients treated with
SGAs, including abnormal weight gain, hyperglycemia and dyslipidemia. While the molecular mechanisms responsible
for these side-effects remain poorly understood, increasing evidence points to a link between SGAs and
adipose tissue depots of white, brown and beige adipocytes. In this review, we survey the present knowledge in
this area, with a particular focus on the molecular aspects of adipocyte biology including differentiation, lipid metabolism, thermogenic function and the browning/beiging processThis work was funded by H2020 Marie Skłodowska-Curie
ActionsITN-TREATMENT (Grant Agreement 721236, European
Commission). We also acknowledge grants RTI2018-094052-B-100
(MICINN/FEDER, Spain), S2017/BMD-3684 MOIR2-CM (Comunidad
de Madrid, Spain) and CIBERdem (ISCIII, Spain)
